CHARACTERIZATION OF NEUROTENSIN-LIKE IMMUNOREACTIVITY IN HUMAN BASAL GANGLIA - INCREASED NEUROTENSIN LEVELS IN SUBSTANTIA-NIGRA IN PARKINSONS-DISEASE

被引:30
|
作者
FERNANDEZ, A
JENNER, P
MARSDEN, CD
DECEBALLOS, ML
机构
[1] CSIC, INST CAJAL, DEPT NEUROPATHOL, NEURODEGENERAT GRP, E-28002 MADRID, SPAIN
[2] UNIV LONDON KINGS COLL, NEURODEGENERAT DIS RES CTR, DIV BIOMED SCI, PHARMACOL GRP, LONDON, ENGLAND
[3] UNIV LONDON, NATL HOSP NEUROL & NEUROSURG, INST NEUROL, DEPT CLIN NEUROL, LONDON, ENGLAND
关键词
NEUROTENSIN; BASAL GANGLIA; PARKINSONS DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC); RADIOIMMUNOASSAY (RIA);
D O I
10.1016/0196-9781(94)00141-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A method that combines high performance liquid chromatography with radioimmunoassay (HPLC/RIA) has been used to characterize neurotensin-like immunoreactivity (NT-IR) in the basal ganglia from control subjects and Parkinson's disease (PD) patients. In samples from the caudate nucleus and putamen, NT-IR eluted as two HPLC peaks. One was indistinguishable from the synthetic tridecapeptide, while the other peak corresponded to oxidized NT, as judged by its chromatographic behaviour and its reaction with the antiserum employed. There were marked discrepancies between the IR detected in crude extracts and that in HPLC purified samples. NT levels (HPLC/RIA) were unaltered in the caudate nucleus, putamen and both segments of the globus pallidus in the parkinsonian brain. In contrast, there was a two-fold increase in NT content: in both zona compacta and zona reticulata of the substantia nigra in PD patients compared to controls. Degeneration of the nigrostriatal pathway and/or prolonged antiparkinsonian treatment in PD appears to alter neurotensin levels in an attempt to activate the dopaminergic nigrostriatal pathway.
引用
收藏
页码:339 / 346
页数:8
相关论文
共 50 条
  • [1] PARKINSONS-DISEASE - DEPLETION OF SUBSTANTIA NIGRA NEUROTENSIN RECEPTORS
    UHL, GR
    WHITEHOUSE, PJ
    PRICE, DL
    TOURTELOTTE, WW
    KUHAR, MJ
    BRAIN RESEARCH, 1984, 308 (01) : 186 - 190
  • [2] COLLOID INCLUSIONS OF THE SUBSTANTIA-NIGRA IN PARKINSONS-DISEASE
    PAPPOLLA, MA
    DUDLEY, AW
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1986, 86 (03) : 399 - 400
  • [3] IRON HISTOCHEMISTRY OF THE SUBSTANTIA-NIGRA IN PARKINSONS-DISEASE
    MORRIS, CM
    EDWARDSON, JA
    NEURODEGENERATION, 1994, 3 (04): : 277 - 282
  • [4] THE ENIGMA OF NEUROMELANIN IN PARKINSONS-DISEASE SUBSTANTIA-NIGRA
    YOUDIM, MBH
    BENSHACHAR, D
    RIEDERER, P
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 1994, (43): : 113 - 122
  • [5] BASAL LIPID-PEROXIDATION IN SUBSTANTIA NIGRA IS INCREASED IN PARKINSONS-DISEASE
    DEXTER, DT
    CARTER, CJ
    WELLS, FR
    JAVOYAGID, F
    AGID, Y
    LEES, A
    JENNER, P
    MARSDEN, CD
    JOURNAL OF NEUROCHEMISTRY, 1989, 52 (02) : 381 - 389
  • [6] GLUTAMATE RECEPTORS IN THE SUBSTANTIA-NIGRA OF PARKINSONS-DISEASE BRAINS
    DIFAZIO, MC
    HOLLINGSWORTH, Z
    YOUNG, AB
    PENNEY, JB
    NEUROLOGY, 1992, 42 (02) : 402 - 406
  • [7] AGING AND PARKINSONS-DISEASE - SUBSTANTIA-NIGRA REGIONAL SELECTIVITY
    FEARNLEY, JM
    LEES, AJ
    BRAIN, 1991, 114 : 2283 - 2301
  • [8] INCREASED IRON-RELATED MRI CONTRAST IN THE SUBSTANTIA-NIGRA IN PARKINSONS-DISEASE
    GORELL, JM
    ORDIDGE, RJ
    BROWN, GG
    DENIAU, JC
    BUDERER, NM
    HELPERN, JA
    NEUROLOGY, 1995, 45 (06) : 1138 - 1143
  • [9] NEUROTENSIN RECEPTORS IN PARKINSONS-DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY - AN AUTORADIOGRAPHIC STUDY IN BASAL GANGLIA
    CHINAGLIA, G
    PROBST, A
    PALACIOS, JM
    NEUROSCIENCE, 1990, 39 (02) : 351 - 360
  • [10] HETEROGENEITY OF MELANIZED NEURONS EXPRESSING NEUROTENSIN RECEPTOR MESSENGER-RNA IN THE SUBSTANTIA-NIGRA AND THE NUCLEUS PARANIGRALIS OF CONTROL AND PARKINSONS-DISEASE BRAIN
    YAMADA, M
    YAMADA, M
    RICHELSON, E
    NEUROSCIENCE, 1995, 64 (02) : 405 - 417